Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762043 · ClinicalTrials.gov registry record · NA
MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments
A NA study, sponsored by Altec.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04762043 is a NA study that has completed, run by Altec. The registered enrollment target is 30 participants.
The verdict
NCT04762043, a NA study, has completed, sponsored by Altec.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication for those with vocal impairments that resulted from surgical treatment of laryngeal and oropharyngeal cancers.
Interventions
- DEVICE Experimental System: MyoVoice
- DEVICE Reference System: Electrolarynx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2023-11-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762043
The ClinicalTrials.gov registry entry for NCT04762043 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altec, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental System: MyoVoice is the first listed.
NCT04762043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04762043 about?
NCT04762043 is a clinical study titled "MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments". This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication ...
What is the current status of trial NCT04762043?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-02-12. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT04762043?
The interventions under investigation include: Experimental System: MyoVoice (DEVICE), Reference System: Electrolarynx (DEVICE).
Who is sponsoring clinical trial NCT04762043?
This trial is sponsored by Altec, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.